Skin Models

Prove ADCC Activityin real human skinFor therapies targeting mast cells, demonstrating antibody-dependent cell-mediated cytotoxicity (ADCC) in complex human tissue is essential.Traditional in vitro assays provide limited context, leaving critical aspects of biological impact unclear. HypoSkin® offers a solution Our ex vivo human skin model lets you assess mast cell depletion in situ, offering a powerful, human-relevant platform to confirm theRead more

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Explore how NativeSkin® supports ethical, human-relevant, and translational research for pharma.

Advancing medical device development with ex vivo human skinMedical devices are evolving rapidly, becoming more sophisticated and diverse in their applications. From injectable drug delivery systems to wound dressings, wearable sensors, and microneedles, these innovations must undergo rigorous testing to ensure safety, functionality, and biocompatibility. However, as medical devices become more complex, so do the challenges associated with their preclinicalRead more

Explore how NativeSkin® supports human-relevant cosmetic efficacy and safety testing, helping you strengthen claims and de-risk formulations earlier.

Beyond animal models: The role of human skin in ADME testingADME (Absorption, Distribution, Metabolism, and Excretion) testing plays a vital role in modern drug development by improving candidate selection, reducing failures, enhancing safety assessments, ensuring regulatory compliance, and ultimately saving time and resources in bringing new drugs to market. Traditionally, ADME testing has relied on animal models and in vitroRead more